{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T06:23:57Z","timestamp":1787207037123,"version":"build-2736575974"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of hetrombopag and eltrombopag in children with cancer therapy-induced thrombocytopenia (CTIT), and to explore the clinical value of eltrombopag for this specific pediatric population given the current lack of dedicated literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a single-center retrospective study. A total of 185 pediatric CTIT patients were enrolled, including 114 cases in the hetrombopag group and 71 cases in the eltrombopag group. Baseline characteristics, platelet (PLT) parameters, efficacy outcomes (platelet response rate, response duration, transfusion dependence), and adverse events (AEs) were compared between the two groups. Statistical analyses were performed using appropriate tests (t-test, Mann\u2013Whitney U test, \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test, and proportional odds logistic regression), with\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05 considered statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics were generally balanced between the two groups, with no significant differences in age, height, weight, primary diagnosis, or baseline PLT count (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;gt;\u202f0.05), except for gender distribution (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.013). Regarding efficacy: (1) Eltrombopag was associated with higher rates of partial or complete platelet response relative to hetrombopag in this retrospective cohort, with an odds ratio (OR) of 1.978 (95% confidence interval [95% CI]: 1.295\u202f~\u202f3.021,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001) after adjusting for confounding factors. (2) The rate of platelet transfusion dependence was significantly lower in the eltrombopag group (15.7% vs. 31.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.019). (3) No significant difference was observed in PLT count at drug withdrawal (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.493) or response duration (39.42\u202f\u00b1\u202f102.99\u202fdays vs. 63.75\u202f\u00b1\u202f129.33\u202fdays,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.192) between the two groups. No significant intergroup differences in response duration were found between hetrombopag and eltrombopag across the primary and three sensitivity analyses (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;gt;\u202f0.05). For safety: (1) The hetrombopag group had higher incidences of Grade 1\u20132 leukopenia (41.2% vs. 23.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.016) and anemia (45.6% vs. 25.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006). (2) The eltrombopag group had a higher incidence of elevated bilirubin levels (69.0% vs. 47.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.028). Thrombocytosis and thrombotic events were rare in both groups with no significant differences (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;gt;\u202f0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In pediatric CTIT patients, eltrombopag was linked to improved platelet response and less transfusion dependence, accompanied by a tolerable safety profile. As the first study focusing on eltrombopag for pediatric CTIT, these findings provide critical evidence supporting its clinical application as a promising therapeutic option for this understudied population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1890229","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:29:00Z","timestamp":1787203740000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety comparison of hetrombopag and eltrombopag in children with cancer therapy-induced thrombocytopenia: a single-center retrospective study"],"prefix":"10.3389","volume":"13","author":[{"given":"Li-Ting","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-An","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Nan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hainan Branch, Shanghai Children\u2019s Medical Center, School of Medicine, Shanghai Jiao Tong University","place":["Sanya, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref1","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.critrevonc.2016.01.005","article-title":"Chemotherapy induced thrombocytopenia in pediatric oncology","volume":"99","author":"Tamamyan","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1200\/JCO.2001.19.5.1519","article-title":"Platelet transfusion for patients with cancer:clinical practice guidelines of the American Society of Clinical Oncology","volume":"19","author":"Schiffer","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1200\/jco.2012.42.7161","article-title":"Guideline for the management of fever and neutropenia in children with cancer and\/or undergoing hematopoietic stem-cell transplantation","volume":"30","author":"Lehrnbecher","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1200\/JOP.2017.028902","article-title":"Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update summary","volume":"14","author":"Schiffer","year":"2018","journal-title":"J Oncol Pract"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1365-2141.2008.07189.x","article-title":"Platelet transfusion refractoriness","volume":"142","author":"Hod","year":"2010","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/10781552231219003","article-title":"Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis","volume":"31","author":"Gurumurthy","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e48855","DOI":"10.1097\/MD.0000000000048855","article-title":"Romiplostim-N01 for cancer therapy-induced thrombocytopenia: a propensity score-matched cohort study","volume":"105","author":"Yu","year":"2026","journal-title":"Medicine"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"848","DOI":"10.19746\/j.cnki.issn.1009-2137.2025.03.033","article-title":"The efficacy of combination of Avatrombopag and rhIL-11 in adult patients of acute myeloid leukemia with Cancer treatment-induced thrombocytopenia","volume":"33","author":"Luo","year":"2025","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.11669\/cpj.2024.15.001","article-title":"Clinical research progress of Hetrombopag in thrombocytopenia","volume":"59","author":"Zhang","year":"2024","journal-title":"Chin Pharm J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1001\/jama.2025.18168","article-title":"Eltrombopag for newly diagnosed pediatric immune thrombocytopenia requiring treatment: the PINES randomized clinical trial","volume":"334","author":"Shimano","year":"2025","journal-title":"JAMA"},{"key":"ref14","year":"2009"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1055\/a-2247-4209","article-title":"Update on the use of Thrombopoietin-receptor agonists in pediatrics","volume":"44","author":"Gebetsberger","year":"2024","journal-title":"Hamostaseologie"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1097\/MPH.0000000000002300","article-title":"Eltrombopag-induced metabolic acidosis and hepatic encephalopathy in pediatric ITP","volume":"44","author":"Hermann","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e43665","DOI":"10.1097\/MD.0000000000043665","article-title":"Successful treatment of refractory cancer therapy-induced thrombocytopenia in a breast cancer patient using romiplostim N01: a case report","volume":"104","author":"Liu","year":"2025","journal-title":"Medicine"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14656566.2023.2198089","article-title":"Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis","volume":"24","author":"Li","year":"2023","journal-title":"Expert Opin Pharmacother"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1890229\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:29:03Z","timestamp":1787203743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1890229\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":19,"alternative-id":["10.3389\/fmed.2026.1890229"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1890229","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1890229"}}